Last reviewed · How we verify
SC interferon beta-1a
At a glance
| Generic name | SC interferon beta-1a |
|---|---|
| Also known as | Rebif |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
- A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS (PHASE3)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (PHASE1)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- Plegridy Satisfaction Study in Participants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC interferon beta-1a CI brief — competitive landscape report
- SC interferon beta-1a updates RSS · CI watch RSS
- Biogen portfolio CI